Showing 1481-1490 of 1690 results for "".
- Research Shows Potential of Smartphone Applications for Brain Health Assessment in Rural Communitieshttps://practicalneurology.com/news/research-shows-potential-of-smartphone-applications-for-brain-health-assessment-in-rural-communities/2470241/Smartphone applications may be an effective, scalable, low-cost, adaptable strategy for assessing brain health in rural communities, according to research presented at the 2023 meeting of the Alzheimer’s Association I
- Study Evaluates Stigma of High-Frequency Headache/Migraine with Acute Medication Overdose as a Factor of Age, Gender, Employment Status, and Race/Ethnicityhttps://practicalneurology.com/news/study-evaluates-stigma-of-high-frequency-headachemigraine-with-acute-medication-overdose-as-a-factor-of-age-gender-employment-status-and-raceethnicity/2470213/Stigma associated with high-frequency headache/migraine with acute medication overdose (HFM+AMO) is more prevalent in employed, non-Hispanic Black male patients aged 18-49 years, according to a new study presented at the 65
- Study Finds Structural Brain Changes in Racially and Ethnically Diverse Patients with Multiple Sclerosishttps://practicalneurology.com/news/study-finds-structural-brain-changes-in-racially-and-ethnically-diverse-patients-with-multiple-sclerosis/2470193/A recent study presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) addressed a critical research gap by identifying an association between race and ethnicity with structural brain cha
- Baseline NfL and GFAP Biomarker Reference Ranges in Healthy Controlshttps://practicalneurology.com/news/baseline-nfl-and-gfap-biomarker-reference-ranges-in-healthy-controls/2470127/Researchers have confirmed previous research results demonstrating an association between age and body mass index (BMI) on plasma neurofilament light chain (NfL) levels and have documented new baseline plasma glial fibrilla
- Four Genetic Markers Connected to Progressive Multifocal Leukoencephalopathyhttps://practicalneurology.com/news/four-genetic-markers-connected-to-progressive-multifocal-leukoencephalopathy/2470084/Scientists whose research has been published in Frontiers in Neurology have identified 4 specific genes associated with progressive multifocal leukoencephalopathy (PML). The 4 genes are C8B, LY9 (
- Subjective Cognitive Decline Linked to Higher Dementia Risk for Black and Latinx Peoplehttps://practicalneurology.com/news/subjective-cognitive-decline-linked-to-higher-dementia-risk-for-black-and-latinx-people/2470072/According to a study published in Neurology, some people report a decline in their memory before the decline is large enough to appear on standardized tests. This subjective cognitive decline is associated with an increased risk of developing dementia in Black and Latinx people. <
- Air Pollution Correlated With High Risk of in-Hospital Death From Strokehttps://practicalneurology.com/news/air-pollution-correlated-with-high-risk-of-in-hospital-death-from-stroke/2469919/A new study published in Neurology states high air pollution has an association with increased in-hospital death from stroke. Study researchers evaluated 3.1 million records of people hospitalized with an
- Antisense Oligonucleotide for Potential Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Decreases Dipeptide Repeat Proteinshttps://practicalneurology.com/news/antisense-oligonucleotide-for-potential-treatment-of-c9orf72-related-amyotrophic-lateral-sclerosis-and-frontotemporal-dementia-decreases-dipeptide-repeat-proteins/2469871/In the ongoing phase 1b/2a FOCUS-C9 clinical trial (NCT04931862) of an antisense oligonucleotide (ASO) (WVE-004; Wave Life Sciences, Cambridge, MA) for potential treatment of C9orf72-associated amyotrophic lateral sclerosis and frontot
- Phase 3 Study of Tolperisone for Muscle Spasms Completes Enrollmenthttps://practicalneurology.com/news/phase-3-study-of-tolperisone-for-muscle-spasms-completes-enrollment/2469759/Enrollment of 1,000 participants is complete for the phase 3 RESUME-1 study (NCT04671082) of tolperisone (Mydocalm; Neurana Pharmaceuticals, San Diego, CA) for muscle spasms associated with acute,
- Ganaxolone Reduces Seizure Frequency in Tuberous Sclerosis Complexhttps://practicalneurology.com/news/ganaxolone-reduces-seizure-frequency-in-tuberous-sclerosis-complex/2469673/In an open-label phase 2 trial (NCT04285346), ganaxolone (Marinus Pharmaceuticals, Radnor, PA) treatment of 23 participants with seizures associated with tuberous sclerosis complex (TSC) reduced s